|Bid||65.54 x 100|
|Ask||65.60 x 100|
|Day's Range||65.54 - 66.27|
|52 Week Range||55.11 - 66.80|
|PE Ratio (TTM)||41.77|
|Earnings Date||Jul 28, 2017|
|Dividend & Yield||1.88 (2.84%)|
|1y Target Est||69.35|
MOSCOW/KIEV/WASHINGTON, June 27 (Reuters) - A major global cyber attack dubbed "GoldenEye" or "Petya" on Tuesday disrupted computers at Russia's biggest oil company, Ukrainian banks and multinational firms with a virus similar to the ransomware virus that last month infected more than 300,000 computers. The attack underscores growing concerns that businesses have failed to secure their networks from increasingly aggressive hackers, who have shown they are capable of shutting down critical infrastructure and crippling corporate and government networks.
In the last decade, no fewer than three major pharmaceutical companies have suffered defeat trying to bring a new class of cholesterol-lowering medication to market.s Much to the surprise of investors, Merck & Co. (MRK) could succeed where Pfizer (PFE), Roche (RHHBY) and Eli Lilly & Co. (LLY) have all failed. Merck has yet to decide if it will seek Food and Drug Administration approval, a sign to some that the company isn’t sure if the study data, though positive, are strong enough to ensure regulatory approval. Thanks to the growing success of Merck’s immunotherapy cancer drug Keytruda, the shares have gained 19% in the past year to near a 52-week high of $66.80.
Global businesses, including Merck, Maersk and Rosneft, reported significant cyberattacks against their computer systems that expert said was ransomware.